Royalty Pharma, plc (RPRX) Rallied on Earnings Beat
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Hedged Equity Fund”.
Posts Tagged ‘NASDAQ:RPRX’
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q1 2026 Earnings Call Transcript May 6, 2026Royalty Pharma plc misses on earnings expectations.
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most undervalued biotech stocks to buy right now. Royalty Pharma Plc (NASDAQ:RPRX) announced on April 17 that its board of directors...
8 Most Undervalued Biotech Stocks to Buy Right Now
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6%
Patient Capital Management, based in Baltimore, released its first-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy,” available for download here.
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations
On February 12, Goldman Sachs raised its price target on Royalty Pharma plc (NASDAQ:RPRX) to $51 from $45 and maintained a Buy rating after strong Q4 results.
Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule
Royalty Pharma (NASDAQ:RPRX) is one of the dirt cheap stocks to buy now.
12 Dirt Cheap Stocks to Buy Now
On February 23, Pierre Ouimet, head investment strategist at UBS Canada, joined BNN Bloomberg to discuss the markets and provide a spotlight on undervalued sectors.
TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here’s Why
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best cheap biotech stocks to buy now.
12 Cheap Biotech Stocks to Buy Now
On February 27, Eli Casdin, Casdin Capital CEO, appeared on CNBC’s ‘Closing Bell’ to talk about the biotech sector.
11 Best Low Priced Growth Stocks to Buy Right Now
Low-priced growth stocks, specifically those combining a low forward P/E ratio with strong or accelerating Earnings Per Share (EPS), offer a compelling blend of value and momentum...
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript February 11, 2026Royalty Pharma plc beats earnings expectations.
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) – Here’s Why
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best healthcare stocks under $50 to invest in.
12 Best Healthcare Stocks Under $50 to Invest In
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage...
Jim Cramer Shared His Takes on These 16 Stocks
On the surface, the stock market seems totally binary, dancing to the tune of a president who likes to take the averages into his own hands and raise or lower them depending upon...
Royalty Pharma plc (NASDAQ:RPRX) Q3 2025 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q3 2025 Earnings Call Transcript November 5, 2025Royalty Pharma plc misses on earnings expectations.
What Do Analysts Think About Royalty Pharma Plc (RPRX)?
Royalty Pharma Plc (NASDAQ:RPRX) is one of the most profitable biotech stocks to buy.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth
Royalty Pharma plc (NASDAQ:RPRX), a leader in biopharma royalties, made major strategic moves in September 2025.
10 Best Pharma Stocks to Buy According to Billionaires
Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United...
TD Cowen Maintains a Buy on Royalty Pharma (RPRX)
Royalty Pharma Plc (NASDAQ:RPRX) is one of the best affordable biotech stocks to invest in now. On September 12, TD Cowen analyst Michael Nedelcovych maintained a Buy rating ...
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in...
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in acquiring and managing royalties from marketed drugs, continues to demonstrate strong growth and ...
12 Cheap Healthcare Stocks to Buy Now
Mizuho health care sector strategist Jared Holz made an appearance on CNBC's "The Exchange" on July 21 to discuss the challenges facing the healthcare industry and whether there...
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program
Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase
Royalty Pharma plc (NASDAQ:RPRX) is one of the most undervalued and overlooked large-cap stocks.
Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal
Royalty Pharma plc (NASDAQ:RPRX) is a leading buyer of biopharmaceutical royalties, holding interests in over 35 commercial products, including Trikafta, Trelegy, Evrysdi, and...
Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines
Royalty Pharma plc (NASDAQ:RPRX) is a leading biopharmaceutical royalty company that invests in and acquires royalty interests in innovative drug products, partnering with biotech...
12 Overlooked Large-Cap Stocks with Low Multiples
A couple of days ago, the brokerage firm Jefferies increased its 2025 target for the S&P 500 index to 6,600, from its earlier target of 5,600.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
10 Overlooked Healthcare Stocks to Invest in
Most Americans have endured the frustration of having their health insurance denied, often with no resolution even after contacting carriers by phone and email.
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT
Royalty Pharma Plc (NASDAQ:RPRX) is one of the top most undervalued biotech stocks to buy now.
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the...
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q2 2025 Earnings Call Transcript August 6, 2025Royalty Pharma plc misses on earnings expectations.
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating
Royalty Pharma plc (NASDAQ:RPRX) is one of the high-margin pharma stocks to buy now.
10 Best High-Margin Pharma Stocks to Buy Now
The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global economic uncertainty.
Royalty Pharma plc (NASDAQ:RPRX) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call.
Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2025 investor letter.
8 Most Undervalued Healthcare Stocks to Buy According to Analysts
Healthcare prices and expenditures have been rising in the United States.
7 Most Profitable Biotech Stocks To Buy Right Now
With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.
15 Best Defensive Stocks Amid Market Volatility
With ongoing inflation, economic uncertainty, and global tensions, more investors are looking for ways to protect their money while still earning steady returns.
10 Best Performing Pharma Stocks So Far in 2025
On February 20, Jared Holz, Mizuho healthcare sector strategist, appeared on 'Squawk Box' to discuss the potential challenges and opportunities the pharmaceutical industry may...
Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call Transcript February 11, 2025Royalty Pharma plc misses on earnings expectations.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks
Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the most successful equity-focused hedge funds in the world.
14 Best 52-Week High Stocks To Buy According to Analysts
After two years of substantial gains to record highs, exhaustion in the US equity markets is slowly kicking in.
Jim Cramer Talked About These 8 Stocks
Jim Cramer, host of Mad Money, recently shared some investment wisdom drawn from his four decades of experience.
Jim Cramer’s Latest Portfolio Heading Into 2025: Top 10 Stocks
Jim Cramer in a latest program reiterated his view that the market is currently oversold and told investors about his methodology of analyzing market selling and buying indicators...
Hedge Fund Resource Center
